9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: Evidence from the Breast Cancer Association Consortium

H Warren; F Dudbridge; O Fletcher; N Orr; N Johnson; JL Hopper; C Apicella; MC Southey; M Mahmoodi; MK Schmidt; A Broeks; S Cornelissen; LM Braaf; KR Muir; A Lophatananon; A Chaiwerawattana; S Wiangnon; PA Fasching; MW Beckmann; AB Ekici; R Schulz-Wendtland; EJ Sawyer; I Tomlinson; M Kerin; B Burwinkel; F Marme; A Schneeweiss; C Sohn; P Guénel; T Truong; P Laurent-Puig; C Mulot; SE Bojesen; SF Nielsen; H Flyger; BG Nordestgaard; RL Milne; J Benítez; JI Arias-Pérez; MP Zamora; H Anton-Culver; A Ziogas; L Bernstein; CC Dur; H Brenner; H Müller; V Arndt; A Langheinz; A Meindl; M Golatta; CR Bartram; RK Schmutzler; H Brauch; C Justenhoven; T Brüning; J Chang-Claude; S Wang-Gohrke; U Eilber; T Dörk; P Schürmann; M Bremer; P Hillemanns; H Nevanlinna; TA Muranen; K Aittomäki; C Blomqvist; N Bogdanova; N Antonenkova; Y Rogov; M Bermisheva; D Prokofyeva; G Zinnatullina; E Khusnutdinova; A Lindblom; S Margolin; A Mannermaa; VM Kosma; JM Hartikainen; V Kataja; G Chenevix-Trench; J Beesley; X Chen; D Lambrechts; A Smeets; R Paridaens; C Weltens; D Flesch-Janys; K Buck; S Behrens; P Peterlongo; L Bernard; S Manoukian; P Radice; FJ Couch; C Vachon; X Wang; J Olson; G Giles; L Baglietto; CA McLean

Journal article

9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: Evidence from the Breast Cancer Association Consortium

H Warren, F Dudbridge, O Fletcher, N Orr, N Johnson, JL Hopper, C Apicella, MC Southey, M Mahmoodi, MK Schmidt, A Broeks, S Cornelissen, LM Braaf, KR Muir, A Lophatananon, A Chaiwerawattana, S Wiangnon, PA Fasching, MW Beckmann, AB Ekici Show all

Cancer Epidemiology Biomarkers and Prevention | AMER ASSOC CANCER RESEARCH | Published : 2012

DOI: 10.1158/1055-9965.EPI-12-0526

Abstract

Background: Our recent genome-wide association study identified a novel breast cancer susceptibility locus at 9q31.2 (rs865686). Methods: To further investigate the rs865686-breast cancer association, we conducted a replication study within the Breast Cancer Association Consortium, which comprises 37 case-control studies (48,394 cases, 50,836 controls). Results: This replication study provides additional strong evidence of an inverse association between rs865686 and breast cancer risk [study-adjusted per G-allele OR, 0.90; 95% confidence interval (CI), 0.88; 0.91, P =2.01 × 10-29] among women of European ancestry. There were ethnic differences in the estimated minor (G)-allele frequency amon..

View full abstract

University of Melbourne Researchers

Melissa Southey Author

Roger Milne Author

Graham Giles Author

Catriona McLean Author

Related Projects (7)

RISK FACTORS, SCREENING, PROPHYLAXIS AND OUTCOMES IN INDIVIDUALS FROM BREAST CANCER FAMILIES: KCONFAB FOLLOW-UP STUDY

Having a strong family history of breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2,..

How can the risk of breast cancer be reduced in those with a strong family history of the disease?

Having a strong family history for breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2..

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Epidemiology of chronic disease, health interventions and DNA studies

NIH AUSTRALIAN BREAST CANCER FAMILY REGISTRY SOUTHEY-HOPPER

DESCRIPTION (provided by applicant): The broad objective of the Breast Cancer Family Registry (Breast CFR) is to establish and maintain a hy..

PLATYPUS

This proposal builds on the applicants’ experience with existing large prospective studies and on studies of families of patients with bowel..

THE HEALTH 2020 COHORT STUDY (HEALTH 2020)

Our aim is to develop appropriate infrastructures necessary to facilitate access by researchers to the accumulated data, including questionn..

Grants

Awarded by European Commission

Funding Acknowledgements

[ "This work was supported by the following sources - ABCFS: National Health and Medical Research Council of Australia, the New South Wales Cancer Council; the Victorian Health Promotion Foundation (Australia); the United States (US) National Cancer Institute, NIH [RFA CA 06 503]; and through cooperative agreements with members of the Breast Cancer Family Registry (CFR) and principal investigators. The University of Melbourne [U01 CA69638] contributed data to this study. ABCS: Dutch Cancer Society [NKI 2001-2423, 2007-3839] and Dutch National Genomics Initiative. ACP: Breast Cancer Research Trust, UK. BBCC: ELAN program of the University Hospital of Erlangen. BBCS: Cancer Research UK [C150/A5660 and C1178/A3947]; Break through Breast Cancer; and NHS funding to the NIHR Biomedical Research Centre and the National Cancer Research Network (NCRN). H. Warren is funded by the UK Medical Research Council [G0801414]. BCAC: Cancer Research UK [C1287/A10118, C1287/A12014] and the European Community's Seventh Framework Programme under grant agreement no. 223175 (HEALTH-F2-2009-223175) (COGS). BCAC meetings have been funded by the European Union COST program [BM0606]. BIGGS: NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London [to E.J. Sawyer]; Oxford Biomedical Research Centre (to I. Tomlinson]. BSUCH: Helmholtz Society; German Cancer Research Center; and Dietmar-Hopp Foundation. CECILE: Fondation de France [2004012618, 2007005156]; Institut National du Cancer (INCa) [2007-1/SPC2, 2008-1-CP-4, 2009-1-SHS/SP-04]; Association pour la Recherche contre le Cancer (ARC) [2008-1-CP-4]; Agence Francaise de Securite Sanitaire de l'Environnement et du Travail (AFSSET - ANSES) [ST-2005-003, EST2008/1/26, and VS-2009-21]; Ligue contre le Cancer Grand Ouest; and Agence Nationale de la Recherche (ANR) [00047-05]. CGPS: Herlev Hospital; Chief Physician Johan Boserup; and Lise Boserup's Fund. CNIO-BCS: Genome Spain Foundation; the Red Tematica de Investigacion Cooperativa en Cancer and grants from the Asociacion Espanola Contra el Cancer; and the Fondo de Investigacion Sanitario [PI081583, PI081120]. CTS: California Breast Cancer Act of 1993; NIH [R01 CA77398]; the Lon V Smith Foundation [LVS39420]; and the California Breast Cancer Research Fund [contract 97-10500]. Collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer-reporting program mandated by California Health and Safety Code Section 103885. ESTHER: Baden-Wurttemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study that was supported by a grant from the Deutsche Krebshilfe (German Cancer Aid). GESBC: Deutsche Krebshilfe e.V. [70492]; and genotyping in part by the state of Baden-Wurttemberg through the Medical Faculty of the University of Ulm [P.685]. GC-HBOC: Deutsche Krebshilfe [107054]; the Dietmar-Hopp Foundation; the Helmholtz society; and the German Cancer Research Centre (DKFZ). GENICA: Federal Ministry of Education and Research (BMBF) Germany [01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114]; Robert Bosch Foundation, Stuttgart; Deutsches Krebsforschungszentrum (DKFZ), Heidelberg; Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, Germany. HABCS: Rudolf Bartling Foundation.", "HEBCS: Helsinki University Central Hospital Research Fund, Academy of Finland [132473]; Finnish Cancer Society; Nordic Cancer Union; and Sigrid Juselius Foundation. HMBCS: Hannelore Munke Stipend [to N. Bogdanova]. HUBCS: German Federal Ministry for Research and Education [RUS 08/017]. KARBAC: Swedish Cancer Society; Stockholm Cancer Society; and Gustav V Jubilee Foundation. KBCP: Finnish Cancer Society; Academy of Finland [127220], special Government Funding (EVO) of Kuopio University Hospital [5654113, 5501]; and strategic funding from the University of Eastern Finland. KConFab-AOCS: National Breast Cancer Foundation; National Health and Medical Research Council (NHMRC); Queensland Cancer Fund; Cancer Councils of New South Wales, Victoria, Tasmania and South Australia; and the Cancer Foundation of Western Australia. The kConFab Clinical Follow Up Study was funded by the NHMRC [145684, 288704, 454508]. Financial support for the AOCS was provided by the US Army Medical Research and Materiel Command [DAMD17-01-1-0729], the Cancer Council of Tasmania and Cancer Foundation of Western Australia and the NHMRC [199600]. G. Chenevix-Trench and P. Webb are supported by the NHMRC. LMBC: 'Stichting tegen Kanker' [232-2008, 196-2010]. MARIE: Deutsche Krebshilfe e.V. [70-2892-BR 1]; Hamburg Society; German Cancer Research Center; and the genotype work in part by the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MBCSG: Ministero della Salute (Extraordinary National Cancer Program 2006 \"Alleanza contro il Cancro\", and \"Progetto Tumori Femminili\") (to P. Radice); Ministero dell'Universita e Ricerca (RBLAO3-BETH; to P. Radice); Fondazione Italiana per la Ricerca sul Cancro (Special Project \"Hereditary tumors\"); Associazione Italiana per la Ricerca sul Cancro (4017; to P. Peterlongo) and by funds from Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects \"5 x 1000\"). MCBCS: NIH [CA122340]; Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201]; the Komen Foundation for the Cure; and the Breast Cancer Research Foundation (BCRF). MCCS: Australian National Health and Medical Research Council [209057, 251533, 396414, 504711], with infrastructure support provided by the Cancer Council Victoria, and cohort recruitment partly funded by VicHealth. NC-BCFR: US National Cancer Institute, NIH [RFA-CA-06-503] and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario [U01 CA69467], the Cancer Prevention Institute of California [U01 CA69417], and The University of Melbourne [U01 CA69638]. Samples from the NC-BCFR were processed and distributed by the Coriell Institute for Medical Research. OBCS: Finnish Cancer Foundation; Academy of Finland; University of Oulu; and Oulu University Hospital. OFBCR: US National Cancer Institute, NIH [RFA-CA-06503] and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario [U01 CA69467], Northern California Cancer Center [U01 CA69417], and University of Melbourne [U01 CA69638] and by Cancer Care Ontario. ORIGO: Dutch Cancer Society [RUL 1997-1505]; and Biobanking and Biomolecular Resources Research Infrastructure [BBMRI-NL CP16]. RBCS: Dutch Cancer Society [DDHK 2004-3124, DDHK 2009-4318]. SASBAC: NIH [RO1 CA58427] [to P. Hillemanns and J.", "Liu]; and the Agency for Science, Technology and Research (A *STAR; Singapore). SBCS: Yorkshire Cancer Research; and Breast Cancer Campaign. SEARCH: Programme grant from Cancer Research UK [C490/A10124]. UCIBCS: US NIH [CA58860, CA92044] and the Lon V Smith Foundation [LVS39420]. UKBGS: Breakthrough Breast Cancer." ]